• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
China Pharmaceuticals & Healthcare 2H 2013 Product Image

China Pharmaceuticals & Healthcare 2H 2013

  • Published: January 2014
  • Region: China
  • 34 Pages
  • Emerging Markets Direct

In China, the government spending on health care grew at a compounded annual growth rate (CAGR) of 32.01% between 2005 and 2012. As a result of rising disposable income and health awareness, health care spending per capita in both urban and rural areas is trending up. Nevertheless, public health care expenditure of total GDP in China still trails many developed economies like the United States, Canada and Germany.

Health care spending per capita in urban and rural China reached RMB 1,064 and RMB 514 respectively in 2012. Public programs in China also drive the rising health care demand. Government spending on public health programs increased at a CAGR of 16.84% from 2001 to 2012. Social security medical fund and private health insurance premiums have risen rapidly over the last decade. The number of retirees insured under the medical fund in urban areas reached 66 million by the end of 2012.

Revenues from the Chinese pharmaceutical industry grew by a CAGR of 23.3% from 2006 to 2012. The Chinese government has allocated RMB 1.49bn to a subsidy fund to support the development of traditional Chinese medicine in 2013. Chemical drugs preparation, Chinese prepared medicine READ MORE >

1. Industry Profile

1.1 Market Size and Value

1.2 Social Security and Health Insurance

1.4 Health Care Infrastructure

1.4 Pharmaceutical Industry Overview

1.5 Regulations and Policies

2. Market Trends and Outlook

2.1 Social Health Care Insurance System

2.2 Traditional Chinese Medicine

2.3 Over-The-Counter (OTC)

2.4 Vaccines

3. Leading Players and Comparative Matrix
3.1 Leading Players

3.1.1 Shanghai Pharmaceuticals Holding Co. Ltd.
3.1.2 China National Accord Medicines Corp. Ltd.

3.1.3 Harbin Pharmaceutical Group Co. Ltd.

3.1.4 Yunnan Baiyao Group Co. Ltd.

3.1.5 Hangzhou Huadong Medicine Co. Ltd.

3.2 Comparative Matrix

3.3 SWOT Analysis

4. Tables and Charts

Table 1: Number of Beds by Type of Hospital
Table 2: New Drug Classifications in China
Table 3: Top 10 Major Traditional Chinese Medicinal Materials
Table 4: Major Type II Vaccines
Table 5: Shanghai Pharma Financial Highlights
Table 6: Sinopharm Accord Financial Highlights
Table 7: Harbin Pharma Financial Highlights
Table 8: Yunnan Baiyao Financial Highlights
Table 9: Huadong Medicine Financial Highlights
Table 10: Selected Peer Comparison of Key Financial Ratios

Chart 1: Total Government Health Care Expenditure
Chart 2: Total Health Care Expenditure over GDP in 2011
Chart 3: Health Care Expenditure per Capita in Urban and Rural China
Chart 4: Total Government Expenditure on Public Health
Chart 5: Social Security Medical Fund in Urban Areas
Chart 6: Retirees in Urban Areas Insured under Social Security Medical Fund
Chart 7: Health Insurance in China
Chart 8: Number of Hospitals in China
Chart 9: Hospitals by Type
Chart 10: Total Asset of Pharmaceutical Industry in China
Chart 11: Revenue and Net Profit Margin of Pharmaceutical Industry in China
Chart 12: Pharmaceutical Industry Revenue by Product Category 1H2013
Chart 13: Pharmaceutical Market by Therapeutic Area 2011
Chart 14: Accumulated Balance of Social Medical Insurance Programs
Chart 15: Revenue of Traditional Chinese Medicine
Chart 16: Distribution Channel of OTC Pharmaceuticals
Chart 17: Shanghai Pharma Segment Revenue 2012
Chart 18: Sinopharm Accord Segment Revenue 2012
Chart 19: Harbin Pharma Segment Revenue 2012
Chart 20: Yunnan Baiyao Segment Revenue 2012
Chart 21: Huadong Medicine Segment Revenue 2012

- China National Accord Medicines Corp. Ltd.

- Hangzhou Huadong Medicine Co. Ltd.

- Harbin Pharmaceutical Group Co. Ltd.

- Shanghai Pharmaceuticals Holding Co. Ltd.
- Yunnan Baiyao Group Co. Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos